• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

我们何时能迎来克隆?从产业角度来看典型的 CLD 时间线。

When will we have a clone? An industry perspective on the typical CLD timeline.

机构信息

Seagen Inc., Cell Line Development, Bothell, Washington, USA.

Bayer AG, Biologics Development, Wuppertal, Germany.

出版信息

Biotechnol Prog. 2024 Jul-Aug;40(4):e3449. doi: 10.1002/btpr.3449. Epub 2024 Mar 13.

DOI:10.1002/btpr.3449
PMID:38477447
Abstract

Cell line development (CLD) represents a complex but highly critical process during the development of a biological drug. To shed light on this crucial workflow, a team of BioPhorum members (authors) has developed and executed surveys focused on the activities and effort involved in a typical CLD campaign. An average of 27 members from different companies that participate in the BioPhorum CLD working group answered surveys covering three distinguishable stages of a standard CLD process: (1) Pre-transfection, including vector design and construction; (2) Transfection, spanning the initial introduction of vector into cells and subsequent selection and analysis of the pools; and (3) Single Cell Cloning and Lead Clone Selection, comprising methods of isolating single cells and confirming clonal origin, subsequent expansion and screening processes, and methods for identifying and banking lead clones. The surveys were very extensive, including a total of 341 questions split between antibody and complex molecule CLD processes. In this survey review, the authors interpret and highlight responses for antibody development and, where relevant, contrast complex molecule development challenges to provide a comprehensive industry perspective on the typical time and effort required to develop a CHO production cell line.

摘要

细胞系开发(CLD)是生物药物开发过程中一个复杂但非常关键的过程。为了深入了解这一关键工作流程,BioPhorum 的一组成员(作者)开发并执行了专注于典型 CLD 活动和投入的调查。来自参与 BioPhorum CLD 工作组的不同公司的平均 27 名成员回答了涵盖标准 CLD 过程三个可区分阶段的调查:(1)转染前,包括载体设计和构建;(2)转染,涵盖载体最初引入细胞以及随后的选择和池分析;以及(3)单细胞克隆和先导克隆选择,包括分离单细胞和确认克隆起源的方法、随后的扩增和筛选过程,以及鉴定和保存先导克隆的方法。调查非常广泛,包括总共 341 个问题,分为抗体和复杂分子 CLD 过程。在本次调查综述中,作者对抗体开发的回答进行了解释和重点突出,并在相关情况下将复杂分子开发挑战进行对比,提供了对开发 CHO 生产细胞系所需的典型时间和投入的全面行业视角。

相似文献

1
When will we have a clone? An industry perspective on the typical CLD timeline.我们何时能迎来克隆?从产业角度来看典型的 CLD 时间线。
Biotechnol Prog. 2024 Jul-Aug;40(4):e3449. doi: 10.1002/btpr.3449. Epub 2024 Mar 13.
2
SPEED-MODE cell line development (CLD): Reducing Chinese hamster ovary (CHO) CLD timelines via earlier suspension adaptation and maximizing time spent in the exponential growth phase.快速模式细胞系开发(CLD):通过更早地进行悬浮适应和最大限度地延长指数生长期来缩短中国仓鼠卵巢(CHO)CLD 时间线。
Biotechnol Prog. 2024 Sep-Oct;40(5):e3479. doi: 10.1002/btpr.3479. Epub 2024 May 8.
3
Genomic barcoding for clonal diversity monitoring and control in cell-based complex antibody production.基于基因组条形码的细胞培养复杂抗体生产中的克隆多样性监测和控制
Sci Rep. 2024 Jun 25;14(1):14587. doi: 10.1038/s41598-024-65323-7.
4
Concurrent transfection of randomized transgene configurations into targeted integration CHO host is an advantageous and cost-effective method for expression of complex molecules.将随机转基因构型共转染到靶向整合的中国仓鼠卵巢(CHO)宿主细胞中,是一种表达复杂分子的有利且具有成本效益的方法。
Biotechnol J. 2021 Apr;16(4):e2000230. doi: 10.1002/biot.202000230. Epub 2020 Dec 30.
5
A deep-well plate enabled automated high-throughput cell line development platform.一种深孔板高通量自动化细胞系开发平台。
Biotechnol Prog. 2024 May-Jun;40(3):e3442. doi: 10.1002/btpr.3442. Epub 2024 Feb 20.
6
Microfluidic chip-based single-cell cloning to accelerate biologic production timelines.基于微流控芯片的单细胞克隆技术加速生物制品研发进程。
Biotechnol Prog. 2021 Nov;37(6):e3192. doi: 10.1002/btpr.3192. Epub 2021 Aug 10.
7
Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones.高产中国仓鼠卵巢细胞克隆的筛选策略
Front Bioeng Biotechnol. 2022 Jun 17;10:858478. doi: 10.3389/fbioe.2022.858478. eCollection 2022.
8
Optimization of cell line development in the GS-CHO expression system using a high-throughput, single cell-based clone selection system.使用高通量单细胞克隆选择系统优化GS-CHO表达系统中的细胞系开发。
J Biosci Bioeng. 2015 Sep;120(3):323-9. doi: 10.1016/j.jbiosc.2015.01.002. Epub 2015 Mar 17.
9
Combining regulated and constitutive protein expression significantly boosts protein expression by increasing productivity without affecting CHO cell growth.通过提高生产力而不影响 CHO 细胞生长,调控和组成型蛋白表达的组合可显著提高蛋白表达水平。
Biotechnol Prog. 2023 May-Jun;39(3):e3337. doi: 10.1002/btpr.3337. Epub 2023 Mar 11.
10
Weak promoters to drive selection marker expression: Improvement of cell line development process for therapeutic protein production in CHO-K1 cells.弱启动子驱动选择标记表达:改善 CHO-K1 细胞治疗性蛋白生产的细胞系开发过程。
J Biotechnol. 2023 Jun 10;369:43-54. doi: 10.1016/j.jbiotec.2023.05.001. Epub 2023 May 4.

引用本文的文献

1
Improving outcomes in intensified processing via optimization of the cell line development workflow.通过优化细胞系开发工作流程来改善强化处理的结果。
Biotechnol Prog. 2025 May-Jun;41(3):e70003. doi: 10.1002/btpr.70003. Epub 2025 Feb 19.
2
Characterization of large transgene integrations in Chinese hamster ovary cells using a bioengineered mammalian transposase.利用生物工程改造的哺乳动物转座酶对中国仓鼠卵巢细胞中的大型转基因整合进行表征。
Biotechnol Prog. 2025 May-Jun;41(3):e3524. doi: 10.1002/btpr.3524. Epub 2025 Jan 23.
3
Assessing the Manufacturability and Critical Quality Attribute Profiles of Anti-IL-8 Immunoglobulin G Mutant Variants.
评估抗白细胞介素-8免疫球蛋白G突变体变体的可制造性和关键质量属性概况。
Mol Pharm. 2024 Dec 2;21(12):6423-6432. doi: 10.1021/acs.molpharmaceut.4c01010. Epub 2024 Nov 7.